Abstract:Background: Ameloblastoma is a rare odontogenic neoplasm frequently located in the mandible. Standard treatment involves radical bone resection and immediate reconstruction, causing functional, aesthetic, and psychological impairments. The BRAF V600E mutation is present in approximately 80% of mandible ameloblastomas, and BRAF inhibitors have demonstrated sustained responses in unresectable cases. Methods: We identified ameloblastoma patients planned for ablative surgery and screened them for BRAF V600E mutation. Neoadjuvant BRAF inhibitors were offered to facilitate jaw preservation surgery. Retrospective data collection encompassed treatment regimens, tolerability, tumor response, and conversion to mandible preservation surgery. Results: Between 2017 and 2022, a total of 11 patients received dabrafenib (n = 6) or dabrafenib with trametinib (n = 5). The median age was 19 (range = 10-83) years. Median treatment duration was 10 (range = 3-20) months. All (100%) patients achieved a radiological response. Ten (91%) patients successfully converted to mandible preservation surgery with residual tumor enucleation. One patient attained complete radiological response, and surgery was not performed. Among the 10 surgically treated patients, all exhibited a pathological response, with 4 achieving near complete response and 6 partial response. At a median follow-up of 14 (range = 7-37) months after surgery, 1 case of recurrence was observed. Grade 1-2 adverse effects were reported in 8 (73%) patients, with a single case of grade 3 (hepatitis). Dose modification was necessary for 3 patients, and 4 experienced treatment interruptions, while 1 patient permanently discontinued therapy. Conclusions: Neoadjuvant BRAF inhibition may offer a safe and effective strategy for organ preservation in mandible ameloblastoma treatment.

BRAF Inhibitor: a Novel Therapy for Ameloblastoma in Mandible

Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach

Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors

BRAF V600E mutation mediates invasive and growth features in ameloblastoma

Targeted therapies in ameloblastomas and amelobastic carcinoma—A systematic review

Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review

Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review

Molecular pathogenesis of ameloblastoma

Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma

Microvascularized Fibula Graft For Mandible Reconstruction After Ameloblastoma Resection.

Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma

Tumor microenvironment of ameloblastoma with a focus on osteoclastogenesis, cell migration, and malignant transformation

Clinicopathological characteristics and diagnostic accuracy of BRAF mutations in ameloblastoma: A Bayesian network analysis

Mandible Reconstruction With Microvascularized Fibula Graft After Ameloblastoma Resection - Case Report.

Bioengineering the ameloblastoma tumour to study its effect on bone nodule formation

Ameloblastic carcinoma of the mandible:case report and review of the literature

Clinicopathologic Study on a Rare Variant of Ameloblastoma with Basal Cell Features.

The 'D–M–C' strategy for conventional ameloblastoma of the mandible: a retrospective study

The importance of BRAF‐V600E mutation to ameloblastoma metabolism

Research Advances in the V-Raf Murine Sarcoma Viral Oncogene Homolog Gene Mutation in Ameloblastoma

Ameloblastic Carcinoma: An Analysis Of 12 Cases With A Review Of The Literature